Abstract:Purpose: In this study, we designed a new linear 6-Hydrazinonicotinamide (HYNIC)-conjugated peptide (HYNIC-KRWrNM) (M-6) and labeled with technetium-99m for gamma imaging of glioblastoma as a αvβ3-positive tumor. We evaluated tumor targeting ability of this radio-peptide and compared with previous 99mTc-labeled HYNIC-conjugated RGD analogue peptides. Procedures: One new linear peptide (HYNIC-KRWrNM) (M-6) was designed and labeled with technetium-99m in the presence of 2-[[1,3-dihydroxy-2-(hydroxymethyl) propan-2-yl] amino] acetic acid (Tricine)/Ethylenediamine-N,N'-diacetic acid (EDDA) as co-ligand system. Then, this 99mTc-labeled peptide ([99mTc]Tc-M-7) was evaluated for in vitro stability in saline and serum, specific binding assay, internalization, and binding affinity (Kd). In addition, we performed biodistribution study and planar imaging on nude mice bearing U87-MG xenograft as a αvβ3-positive tumor. Results: The radiochemical yield of [99mTc]Tc-M-7 was obtained ˃95%. This 99mTc-labeled peptide remained stable and intact in saline solution after 24 h incubation. In addition, metabolic stability of this 99mTc-labeled peptide was obtained ˃60% after 4 h incubation in serum. The Kd value for [99mTc]Tc-M-7 was obtained 5.2 ± 1.0 nM. Based on biodistribution results in nude mice bearing U87-MG xenograft, tumor/muscle activity ratio was 6.22 and decreased to 1.89 in blocking group at the same time point (4 h p.i.). The blocking experiment results also indicated that tumor uptake and kidney uptake were αvβ3-mediated. In comparison with previous HYNIC-conjugated RGD analogue peptides, kidneys had the highest uptake of this 99mTc-labeled peptide (52.29 ± 11.48 at 1.5 h p.i. and 27.04 ± 0.66%ID/g at 4 h p.i.). Finally, similar to previous 99mTc-labeled HYNIC-conjugated RGD analogue peptides, [99mTc]Tc-M-7 showed acceptable tumor uptake after 4 h post-injection (based on ROI technique, target-to-background activity ratio = 3.80). Conclusions: This small linear 99mTc-labeled peptide, with high affinity to αvβ3 integrin, desirable water solubility, and cost efficient, demonstrates a potent tumor targeting ability as well as previous HYNIC-conjugated RGD analogue peptides. Hence, [99mTc]Tc-M-7 can be of service to as a new candidate for early detection of αvβ3-positive tumors.

Synthesis and Biological Studies of 99m Tc(HYNIC–MFL)(tricine)(TPPTS) As a Novel Tumor Imaging Agent

Application of 99mTc-Labeled WL12 Peptides as a Tumor PD-L1-Targeted SPECT Imaging Agent: Kit Formulation, Preclinical Evaluation, and Study on the Influence of Coligands

<sup>99m</sup>Tc-Labeled Bombesin(7−14)NH<sub>2</sub>with Favorable Properties for SPECT Imaging of Colon Cancer

Tc-99m-Labeled Bombesin(7-14)Nh2 With Favorable Properties For Spect Imaging Of Colon Cancer

(99M)tc-Labeled Dimeric Octreotide Peptide: a Radiotracer with High Tumor Uptake for Single-Photon Emission Computed Tomography Imaging of Somatostatin Receptor Subtype 2-Positive Tumors.

99m Tc-labeled colchicine for tumor imaging using DTPA as bifunctional chelating agent

99Mtc-Labeling and Evaluation of a HYNIC Modified Small-Molecular Inhibitor of Prostate-Specific Membrane Antigen.

Synthesis and Biodistribution of 99Mtc-Peptides Conjugated Adenine As Tumor Imaging Agents

[ 99m Tc]Tc-labeled HYNIC conjugated chlorambucil as a tumor targeting Agent: Synthesis, characterization and ex-vivo evaluation

Synthesis and Biodistribution of 99Tcm-MAG2-Ade as A Tumor Imaging Agent

Preparation and Evaluation of Tc-99m-Labeled Dimeric Tyr(3)-Octreotide in the Ar42j Tumor Model

SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99Mtc-Hynic-h6f in Breast Cancer Mouse Models.

Technetium-99m-labeling and synthesis of thymidine analogs: potential candidates for tumor imaging.

Breast tumor targeting with (99m)Tc-HYNIC-PR81 complex as a new biologic radiopharmaceutical

Technetium 99m–labeled VQ Peptide: A New Imaging Agent for the Early Detection of Tumors or Premalignancies

Novel 99mTc-Labeled Mannose Derivative as a Highly Promising Single Photon Emission Computed Tomography Probe for Tumor Imaging

Dosimetry estimation and preliminary clinical application of [99mTc]Tc-HYNIC-PSMA-XL-2 in prostate cancer

[99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor

Synthesis and Preliminary Study of 99m Tc-Labeled HYNIC-FAPi for Imaging of Fibroblast Activation Proteins in Tumors

Preparation and Biological Evaluation of 99Mtc-N4ipa for Single Photon Emission Computerized Tomography Imaging of Hypoxia in Mouse Tumor

Small-Animal Spect/Ct Imaging with 99Mtc-Hynic-h10f Detects Her2 Expression in Mice Bearing Human Breast Cancers